In 2024 and as of 30 of April, approximately 240 000 CHIKVD cases and over 90 deaths have been reported worldwide. A total of 18 countries reported CHIKVD cases from the Americas (11), Asia (6), and Africa (1).
Since the beginning of 2024, over 7.5 million dengue cases and over 3 000 dengue-related deaths have been reported from 73 countries/territories. Most cases globally have been reported from the WHO PAHO region, with Brazil reporting most cases.
Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
ECDC is organising a physical workshop between 16 and 18 April 2024 with national experts to develop a public health guidance to support the assessment of the risk of locally-acquired Aedes-borne viral diseases in the EU/EEA.
In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.